Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack Patients' bleeding risk tracked after blood thinner switch

NCT ID NCT04471870

Knowledge-focused Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study followed over 1,000 people who had a heart attack and were given a quick-acting intravenous blood thinner called cangrelor during a procedure to open blocked arteries. Researchers wanted to see how often bleeding occurred when patients then switched to a different oral blood thinner. The goal was to gather real-world safety information, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cangrelor (intravenous blood thinner)
What this could lead to
If results are positive, it could confirm that switching from cangrelor to other blood thinners is safe in real-world practice.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Bleeding risks may still vary by patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,005 people

The number who actually took part.

Started

Oct 2020

Finished

Jan 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. according to the clinical practice

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients' written informed and privacy consent obtained before or at the end of the PCI procedure according to patients' condition but in any case, prior to collection of any study-related data; 2. Male or female patients aged ≥ 18 years; 3. Patients with acute coronary syndromes undergoing PCI; 4. Patients who are planned to be treated with cangrelor, or who have received treatment with cangrelor. Exclusion Criteria: 1. Patients with active bleeding or increased risk of bleeding, because of impaired haemostasis and/or irreversible coagulation disorders or due to recent major surgery/trauma or uncontrolled severe hypertension; 2. Patients with history of stroke or transient ischaemic attack (TIA); 3. Patients with hypersensitivity to the active substance (cangrelor) or to any of its excipients; 4. Known pregnancy or breast-feeding female patients; 5. Patients with stable angina (SA).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome

Contacts and locations

Locations

  • A.O. Mauriziano

    Torino, Italy

  • A.O. Padova

    Padova, Italy

  • A.O. Sant'Anna e San Sebastiano

    Caserta, Italy

  • A.O.R.N. A. Cardarelli

    Naples, Italy

  • A.O.U. Careggi

    Florence, Italy

  • A.O.U. Consorziale Policlinico

    Bari, Italy

  • A.O.U. Federico II

    Naples, Italy

  • A.O.U. Policlinico-Vittorio Emanuele P.O. Ferrarotto

    Catania, Italy

  • A.O.U. Riuniti

    Ancona, Italy

  • A.O.U. Sassari

    Sassari, Italy

  • ASO Santa Croce e Carle

    Cuneo, Italy

  • Aurelia Hospital

    Roma, Italy

  • Azienda Ospedaliera San Pio

    Benevento, Italy

  • Centro Cardiologico Monzino

    Milan, Italy

  • Fondazione Poliambulanza

    Brescia, Italy

  • Fondazione Policlinico Universitario A. Gemelli

    Roma, Italy

  • Fondazione Toscana "G. Monasterio" Ospedale del Cuore G. Pasquinucci

    Massa, Italy

  • Ospedale Ca' Foncello

    Treviso, Italy

  • Ospedale Fabrizio Spaziani

    Frosinone, Italy

  • Ospedale Maggiore

    Bologna, Italy

  • Ospedale S. Andrea

    La Spezia, Italy

  • Ospedale SS Annunziata

    Cosenza, Italy

  • Ospedale San Bassiano

    Bassano del Grappa, Italy

  • Ospedale San Donato

    Arezzo, Italy

  • Ospedale Santa Chiara

    Trento, Italy

  • Ospedale Santa Maria Goretti

    Latina, Italy

  • Ospedale Umberto I

    Syracuse, Italy

  • Ospedale degli Infermi

    Rivoli, Italy

  • Policlinico San Matteo

    Pavia, Italy

  • San Camillo Forlanini

    Roma, 00152, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.